Christopher Nevala-Plagemann
( out of 81 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

Sugar House Health Center

Salt Lake City
801-581-2000

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 81 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    February 22, 2024
    SUGAR HOUSE HEALTH CENTER

    Absolutely great Dr. ! We are very grateful to have him with us.

    January 23, 2024
    SUGAR HOUSE HEALTH CENTER

    My family I are grateful to Dr. NEVALA for all he and his staff have done to help in my care.

    December 21, 2023
    SUGAR HOUSE HEALTH CENTER

    best doctor and staff you could hope for

    December 12, 2023
    SUGAR HOUSE HEALTH CENTER

    Thank you for taking the time to know me as person not just a case. You understand that what people are going through is a life changing event.

    November 30, 2023
    SUGAR HOUSE HEALTH CENTER

    Very knowledgeable and takes time to answer questions.

    November 21, 2023
    SUGAR HOUSE HEALTH CENTER

    Thanks for your continued support

    November 08, 2023
    SUGAR HOUSE HEALTH CENTER

    seems very caring about me as a person and up on the latest medical techniques.

    October 27, 2023
    SUGAR HOUSE HEALTH CENTER

    As I stated I felt true and genuine concern for my well being and the best treatment for given my situation.

    October 26, 2023
    SUGAR HOUSE HEALTH CENTER

    Very down to earth and personable. Great communication. Asked for my input.

    See More Patient Comments

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Hematology/Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. (Read full article)
    2. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. (Read full article)
    3. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. (Read full article)
    4. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. (Read full article)
    5. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. (Read full article)
    6. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. (Read full article)
    7. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. (Read full article)
    8. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. (Read full article)
    9. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. (Read full article)
    10. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123. (Read full article)
    11. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. (Read full article)
    12. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. (Read full article)
    13. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. (Read full article)

    Review

    1. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. (Read full article)
    2. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. (Read full article)
    3. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. (Read full article)

    Case Report

    1. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. (Read full article)
    2. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. (Read full article)

  • News & Podcasts